{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:00:46Z","timestamp":1779163246382,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10557-024-07622-9","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T03:02:44Z","timestamp":1724900564000},"page":"811-822","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative Efficacy of Colchicine and Intensive Low-density Lipoprotein Cholesterol Lowering in Patients with Atherosclerotic Diseases receiving Statins: A Network Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"39","author":[{"given":"Zhenhong","family":"Ou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangchao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunlin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boli","family":"Ran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuehui","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8819-9444","authenticated-orcid":false,"given":"Kun","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"key":"7622_CR1","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMoa021993","volume":"347","author":"PM Ridker","year":"2002","unstructured":"Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557\u201365. https:\/\/doi.org\/10.1056\/NEJMoa021993.","journal-title":"N Engl J Med"},{"key":"7622_CR2","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","volume":"592","author":"P Libby","year":"2021","unstructured":"Libby P. The changing landscape of atherosclerosis. Nat. 2021;592:524\u201333. https:\/\/doi.org\/10.1038\/s41586-021-03392-8.","journal-title":"Nat"},{"key":"7622_CR3","doi-asserted-by":"publisher","first-page":"e002128","DOI":"10.1161\/jaha.115.002128","volume":"4","author":"GJ Mart\u00ednez","year":"2015","unstructured":"Mart\u00ednez GJ, Robertson S, Barraclough J, et al. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. J Am Heart Assoc. 2015;4:e002128. https:\/\/doi.org\/10.1161\/jaha.115.002128.","journal-title":"J Am Heart Assoc"},{"key":"7622_CR4","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1161\/circulationaha.112.122556","volume":"126","author":"PM Ridker","year":"2012","unstructured":"Ridker PM, Howard CP, Walter V, et al. Effects of interleukin-1\u03b2 inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circ. 2012;126:2739\u201348. https:\/\/doi.org\/10.1161\/circulationaha.112.122556.","journal-title":"Circ."},{"key":"7622_CR5","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"JC Tardif","year":"2019","unstructured":"Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa1912388.","journal-title":"N Engl J Med."},{"key":"7622_CR6","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","volume":"383","author":"SM Nidorf","year":"2020","unstructured":"Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with chronic coronary disease. N Engl J Med. 2020;383:1838\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2021372.","journal-title":"N Engl J Med."},{"key":"7622_CR7","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1410489.","journal-title":"N Engl J Med."},{"key":"7622_CR8","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"N Engl J Med."},{"key":"7622_CR9","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med."},{"key":"7622_CR10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/m14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777\u201384. https:\/\/doi.org\/10.7326\/m14-2385.","journal-title":"Ann Intern Med."},{"key":"7622_CR11","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. Bmj. 2011;343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928.","journal-title":"Bmj."},{"key":"7622_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1471-2288-13-35","volume":"13","author":"U Krahn","year":"2013","unstructured":"Krahn U, Binder H, K\u00f6nig J. A graphical tool for locating inconsistency in network meta-analyses. BMC Med Res Methodol. 2013;13:35. https:\/\/doi.org\/10.1186\/1471-2288-13-35.","journal-title":"BMC Med Res Methodol."},{"key":"7622_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","volume":"15","author":"G R\u00fccker","year":"2015","unstructured":"R\u00fccker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2015;15:58. https:\/\/doi.org\/10.1186\/s12874-015-0060-8.","journal-title":"BMC Med Res Methodol."},{"key":"7622_CR14","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","volume":"61","author":"SM Nidorf","year":"2013","unstructured":"Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61:404\u201310. https:\/\/doi.org\/10.1016\/j.jacc.2012.10.027.","journal-title":"J Am Coll Cardiol."},{"key":"7622_CR15","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1161\/circulationaha.120.050771","volume":"142","author":"DC Tong","year":"2020","unstructured":"Tong DC, Quinn S, Nasis A, et al. Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial. Circulation. 2020;142:1890\u2013900. https:\/\/doi.org\/10.1161\/circulationaha.120.050771.","journal-title":"Circulation."},{"key":"7622_CR16","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1186\/s12872-021-02393-9","volume":"21","author":"M Akrami","year":"2021","unstructured":"Akrami M, Izadpanah P, Bazrafshan M, et al. Effects of colchicine on major adverse cardiac events in next 6-month period after acute coronary syndrome occurrence; a randomized placebo-control trial. BMC Cardiovasc Disord. 2021;21:583. https:\/\/doi.org\/10.1186\/s12872-021-02393-9.","journal-title":"BMC Cardiovasc Disord."},{"key":"7622_CR17","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1253\/circj.CJ-19-0412","volume":"83","author":"J Ako","year":"2019","unstructured":"Ako J, Hibi K, Tsujita K, et al. Effect of Alirocumab on coronary atheroma volume in Japanese Patients with acute coronary syndrome- the ODYSSEY J-IVUS trial. Circ J. 2019;83:2025\u201333. https:\/\/doi.org\/10.1253\/circj.CJ-19-0412.","journal-title":"Circ J."},{"key":"7622_CR18","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/jama.2022.5218","volume":"327","author":"L R\u00e4ber","year":"2022","unstructured":"R\u00e4ber L, Ueki Y, Otsuka T, et al. Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. Jama. 2022;327:1771\u201381. https:\/\/doi.org\/10.1001\/jama.2022.5218.","journal-title":"Jama."},{"key":"7622_CR19","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382:1507\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1912387.","journal-title":"N Engl J Med."},{"key":"7622_CR20","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","volume":"376","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Revkin J, Amarenco P, et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med. 2017;376:1527\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1701488.","journal-title":"N Engl J Med."},{"key":"7622_CR21","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1093\/eurheartj\/ehx162","volume":"38","author":"N Hagiwara","year":"2017","unstructured":"Hagiwara N, Kawada-Watanabe E, Koyanagi R, et al. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. Eur Heart J. 2017;38:2264\u201376. https:\/\/doi.org\/10.1093\/eurheartj\/ehx162.","journal-title":"Eur Heart J."},{"key":"7622_CR22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jacc.2015.05.065","volume":"66","author":"K Tsujita","year":"2015","unstructured":"Tsujita K, Sugiyama S, Sumida H, et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol. 2015;66:495\u2013507. https:\/\/doi.org\/10.1016\/j.jacc.2015.05.065.","journal-title":"J Am Coll Cardiol."},{"key":"7622_CR23","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","volume":"36","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statin: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36:1186\u201394. https:\/\/doi.org\/10.1093\/eurheartj\/ehv028.","journal-title":"Eur Heart J."},{"key":"7622_CR24","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","volume":"380","author":"KK Ray","year":"2019","unstructured":"Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380:1022\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1803917.","journal-title":"N Engl J Med."},{"key":"7622_CR25","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1001\/jama.2019.16585","volume":"322","author":"AC Goldberg","year":"2019","unstructured":"Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statin on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial. Jama. 2019;322:1780\u20138. https:\/\/doi.org\/10.1001\/jama.2019.16585.","journal-title":"Jama."},{"key":"7622_CR26","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1161\/strokeaha.121.034388","volume":"52","author":"PJ Kelly","year":"2021","unstructured":"Kelly PJ, Lemmens R, Tsivgoulis G. Inflammation and stroke risk: a new target for prevention. Stroke. 2021;52:2697\u2013706. https:\/\/doi.org\/10.1161\/strokeaha.121.034388.","journal-title":"Stroke."},{"key":"7622_CR27","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/s0140-6736(12)60110-x","volume":"379","author":"DI Swerdlow","year":"2012","unstructured":"Swerdlow DI, Holmes MV, Kuchenbaecker KB, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379:1214\u201324. https:\/\/doi.org\/10.1016\/s0140-6736(12)60110-x.","journal-title":"Lancet."},{"key":"7622_CR28","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459\u201372. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144.","journal-title":"Eur Heart J"},{"key":"7622_CR29","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/s0140-6736(23)00215-5","volume":"401","author":"PM Ridker","year":"2023","unstructured":"Ridker PM, Bhatt DL, Pradhan AD, et al. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. Lancet. 2023;401:1293\u2013301. https:\/\/doi.org\/10.1016\/s0140-6736(23)00215-5.","journal-title":"Lancet."},{"issue":"18","key":"7622_CR30","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/eurjpc\/zwad221","volume":"30","author":"PM Burger","year":"2023","unstructured":"Burger PM, Dorresteijn JAN, Fiolet ATL, et al. Individual lifetime benefit from low-dose colchicine in patients with chronic coronary artery disease. Eur J Prev Cardiol. 2023;30(18):1950\u201362. https:\/\/doi.org\/10.1093\/eurjpc\/zwad221.","journal-title":"Eur J Prev Cardiol."},{"key":"7622_CR31","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1056\/NEJMoa1809798","volume":"380","author":"PM Ridker","year":"2019","unstructured":"Ridker PM, Everett BM, Pradhan A, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019;380:752\u201362. https:\/\/doi.org\/10.1056\/NEJMoa1809798.","journal-title":"N Engl J Med."},{"key":"7622_CR32","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1001\/jama.2013.282836","volume":"311","author":"SJ Nicholls","year":"2014","unstructured":"Nicholls SJ, Kastelein JJ, Schwartz GG, et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. Jama. 2014;311:252\u201362. https:\/\/doi.org\/10.1001\/jama.2013.282836.","journal-title":"Jama."},{"key":"7622_CR33","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/jama.2014.11061","volume":"312","author":"ML O'Donoghue","year":"2014","unstructured":"O\u2019Donoghue ML, Braunwald E, White HD, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. Jama. 2014;312:1006\u201315. https:\/\/doi.org\/10.1001\/jama.2014.11061.","journal-title":"Jama."},{"key":"7622_CR34","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1161\/circresaha.118.311362","volume":"122","author":"A Grebe","year":"2018","unstructured":"Grebe A, Hoss F, Latz E. NLRP3 Inflammasome and the IL-1 pathway in atherosclerosis. Circ Res. 2018;122:1722\u201340. https:\/\/doi.org\/10.1161\/circresaha.118.311362.","journal-title":"Circ Res."},{"key":"7622_CR35","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","volume":"45","author":"YY Leung","year":"2015","unstructured":"Leung YY, Yao Hui LL, Kraus VB. Colchicine\u2013update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45:341\u201350. https:\/\/doi.org\/10.1016\/j.semarthrit.2015.06.013.","journal-title":"Semin Arthritis Rheum."},{"key":"7622_CR36","doi-asserted-by":"publisher","first-page":"713007","DOI":"10.3389\/fphar.2021.713007","volume":"12","author":"W Ma","year":"2021","unstructured":"Ma W, Pan Q, Pan D, et al. Efficacy and safety of lipid-lowering drugs of different intensity on clinical outcomes: a systematic review and network meta-analysis. Front Pharmacol. 2021;12:713007. https:\/\/doi.org\/10.3389\/fphar.2021.713007.","journal-title":"Front Pharmacol."},{"key":"7622_CR37","doi-asserted-by":"publisher","first-page":"e069116","DOI":"10.1136\/bmj-2021-069116","volume":"377","author":"SU Khan","year":"2022","unstructured":"Khan SU, Yedlapati SH, Lone AN, et al. PCSK9 inhibitor and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis. Bmj. 2022;377:e069116. https:\/\/doi.org\/10.1136\/bmj-2021-069116.","journal-title":"Bmj."},{"key":"7622_CR38","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","volume":"13","author":"XL Zhang","year":"2015","unstructured":"Zhang XL, Zhu QQ, Zhu L, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 2015;13:123. https:\/\/doi.org\/10.1186\/s12916-015-0358-8.","journal-title":"BMC Med."},{"key":"7622_CR39","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","volume":"316","author":"MG Silverman","year":"2016","unstructured":"Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. Jama. 2016;316:1289\u201397. https:\/\/doi.org\/10.1001\/jama.2016.13985.","journal-title":"Jama."},{"key":"7622_CR40","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/s0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statin. Lancet. 2005;366:1267\u201378. https:\/\/doi.org\/10.1016\/s0140-6736(05)67394-1.","journal-title":"Lancet."},{"key":"7622_CR41","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","volume":"388","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388:1353\u201364. https:\/\/doi.org\/10.1056\/NEJMoa2215024.","journal-title":"N Engl J Med."},{"key":"7622_CR42","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1093\/eurheartj\/ehab115","volume":"42","author":"ATL Fiolet","year":"2021","unstructured":"Fiolet ATL, Opstal TSJ, Mosterd A, et al. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. Eur Heart J. 2021;42:2765\u201375. https:\/\/doi.org\/10.1093\/eurheartj\/ehab115.","journal-title":"Eur Heart J."},{"key":"7622_CR43","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s00392-023-02254-9","volume":"112","author":"T Chen","year":"2023","unstructured":"Chen T, Liu G, Yu B. A meta-analysis evaluating efficacy and safety of colchicine for prevention of major cardiovascular events in patients with coronary artery disease. Clin Res Cardiol. 2023;112:1487\u2013505. https:\/\/doi.org\/10.1007\/s00392-023-02254-9.","journal-title":"Clin Res Cardiol."}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07622-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-024-07622-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07622-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T03:37:17Z","timestamp":1753501037000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-024-07622-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["7622"],"URL":"https:\/\/doi.org\/10.1007\/s10557-024-07622-9","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,29]]},"assertion":[{"value":"19 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}